Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oenothera Biennis Oil Soft Capsule, marketed under the brand name Taizhiao, is an oral formulation of evening primrose oil developed by Dalian Aosen Pharmaceutical and its subsidiary Dalian Mingsen Pharmaceutical. The oil is a concentrated source of gamma-linolenic acid (GLA), an omega-6 fatty acid. Upon ingestion, GLA is metabolically converted into dihomo-gamma-linolenic acid (DGLA) and subsequently into prostaglandin E1 (PGE1). PGE1 acts as an agonist at prostaglandin E receptors, mediating anti-inflammatory, vasodilatory, and anti-platelet effects. In China, this product is approved as a pharmaceutical for the treatment of hyperlipidemia and the prevention of atherosclerosis, and it is also utilized as a nutraceutical for managing premenstrual syndrome and skin conditions like atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oenothera Biennis Oil Soft Capsule.